SML3517
Fluindione
≥98% (HPLC)
Synonym(s):
2-(4-Fluorophenyl)-1H-indene-1,3(2H)-dione, 2-(4-Fluorophenyl)indene-1,3-dione
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C15H9FO2
CAS Number:
Molecular Weight:
240.23
UNSPSC Code:
51111800
NACRES:
NA.77
MDL number:
Quality Level
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
SMILES string
O=C1C2=C(C(C1C3=CC=C(C=C3)F)=O)C=CC=C2
InChI
1S/C15H9FO2/c16-10-7-5-9(6-8-10)13-14(17)11-3-1-2-4-12(11)15(13)18/h1-8,13H
InChI key
NASXCEITKQITLD-UHFFFAOYSA-N
Related Categories
Biochem/physiol Actions
Fluindione is an orally active vitamin K antagonist (VKA) that exerts its in vivo anticoagulant efficacy by inhibiting the vitamin K epoxide reductase activity (VKOR IC50 = 6.6 nM) in a substrate-comeptitive manner.
Orally active vitamin K antagonist (VKA) that exerts its in vivo anticoagulant efficacy by inhibiting the vitamin K epoxide reductase (VKOR) activity.
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Role of ABC transporters in trans-epithelial transport of vitamin K antagonists
Bernadette Espana , Caroline Prouillac
Biopharmaceutics & Drug Disposition, 38, 20-32 (2017)
Antithrombotic efficacy of the vitamin K antagonist fluindione in a human Ex vivo model of arterial thrombosis : effect of anticoagulation level and combination therapy with aspirin
Bossavy JP, Sakariassen KS, Thalamas C, Boneu B, Cadroy Y
Arteriosclerosis, Thrombosis, and Vascular Biology, 19, 2269-2275 (1999)
Xuejie Chen et al.
Blood, 132(18), 1974-1984 (2018-08-10)
Warfarin, acenocoumarol, phenprocoumon, and fluindione are commonly prescribed oral anticoagulants for the prevention and treatment of thromboembolic disorders. These anticoagulants function by impairing the biosynthesis of active vitamin K-dependent coagulation factors through the inhibition of vitamin K epoxide reductase (VKOR).
Jonaz Font et al.
Fundamental & clinical pharmacology, 32(4), 378-391 (2018-03-12)
Whether oral anticoagulants, vitamin K antagonists (VKAs), and nonvitamin K oral anticoagulant (NOACs) frequently prescribed to atrial fibrillation (AF) patients, do themselves have a pro- or anti-arrhythmic effect have never been addressed. Transmembrane action potentials were recorded in an acute
Global Trade Item Number
| SKU | GTIN |
|---|---|
| SML3517-50MG | 04065268964729 |
| SML3517-10MG | 04065268964712 |
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service